The Impact of Diabetes and Prediabetes on Prevalence of
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
29
04
2022
accepted:
28
06
2022
entrez:
24
11
2022
pubmed:
25
11
2022
medline:
25
11
2022
Statut:
epublish
Résumé
It is uncertain whether diabetes affects the risk of developing latent tuberculosis infection (LTBI) following exposure to In this cross-sectional study, we performed interferon-γ release assays, TB symptom screening, and point-of-care glycolated hemoglobin (HbA1c) testing among HHCs of active TB cases. Diabetes status was classified into diabetes (HbA1c ≥6.5% or self-reported diagnosis), prediabetes (5.7%-6.4%), and euglycemia (≤5.6%). Multivariable logistic regression was used to determine the association of diabetes with LTBI. Among 597 study participants, 123 (21%) had dysglycemia including diabetes (n = 31) or prediabetes (n = 92); 423 (71%) participants were diagnosed with LTBI. Twelve of 31 (39%) HHCs with diabetes were previously undiagnosed with diabetes. The prevalence of LTBI among HHCs with diabetes, prediabetes, and euglycemia was 87% (27/31), 73% (67/92), and 69% (329/474), respectively. In multivariable analysis adjusted for age, sex, and HIV status, the odds of LTBI among HHCs with diabetes were 2.33 (95% confidence interval [CI], .76-7.08) times the odds of LTBI without diabetes. When assessing interaction with age, the association of diabetes and LTBI was robust among participants aged ≥40 years (adjusted odds ratio [aOR], 3.68 [95% CI, .77-17.6]) but not those <40 years (aOR, 1.15 [95% CI, .22-6.1]). HHCs with diabetes may be more likely to have LTBI than those with euglycemia. Further investigations are needed to assess mechanisms by which diabetes may increase risk of LTBI after
Sections du résumé
Background
UNASSIGNED
It is uncertain whether diabetes affects the risk of developing latent tuberculosis infection (LTBI) following exposure to
Methods
UNASSIGNED
In this cross-sectional study, we performed interferon-γ release assays, TB symptom screening, and point-of-care glycolated hemoglobin (HbA1c) testing among HHCs of active TB cases. Diabetes status was classified into diabetes (HbA1c ≥6.5% or self-reported diagnosis), prediabetes (5.7%-6.4%), and euglycemia (≤5.6%). Multivariable logistic regression was used to determine the association of diabetes with LTBI.
Results
UNASSIGNED
Among 597 study participants, 123 (21%) had dysglycemia including diabetes (n = 31) or prediabetes (n = 92); 423 (71%) participants were diagnosed with LTBI. Twelve of 31 (39%) HHCs with diabetes were previously undiagnosed with diabetes. The prevalence of LTBI among HHCs with diabetes, prediabetes, and euglycemia was 87% (27/31), 73% (67/92), and 69% (329/474), respectively. In multivariable analysis adjusted for age, sex, and HIV status, the odds of LTBI among HHCs with diabetes were 2.33 (95% confidence interval [CI], .76-7.08) times the odds of LTBI without diabetes. When assessing interaction with age, the association of diabetes and LTBI was robust among participants aged ≥40 years (adjusted odds ratio [aOR], 3.68 [95% CI, .77-17.6]) but not those <40 years (aOR, 1.15 [95% CI, .22-6.1]).
Conclusions
UNASSIGNED
HHCs with diabetes may be more likely to have LTBI than those with euglycemia. Further investigations are needed to assess mechanisms by which diabetes may increase risk of LTBI after
Identifiants
pubmed: 36420425
doi: 10.1093/ofid/ofac323
pii: ofac323
pmc: PMC9595051
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac323Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR002382
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002378
Pays : United States
Investigateurs
Joel Ernst
(J)
Rafi Ahmed
(R)
Lisa Sharling
(L)
Devin Columbus
(D)
Lance Waller
(L)
Lisa Elon
(L)
Andrea Knezevic
(A)
Shirin Jabbarzadeh
(S)
Hao Wu
(H)
Seegar Swanson
(S)
Yunyun Chen
(Y)
Jyothi Rengarajan
(J)
Cheryl Day
(C)
Wendy Whatney
(W)
Melanie Quezada
(M)
Loren Sasser
(L)
Ranjna Madan Lala
(R)
Tawania Fergus
(T)
Paul Ogongo
(P)
Anthony Tran
(A)
Toidi Adekambi
(T)
Deepak Kaushal
(D)
Toidi Adekambi
(T)
Nadia Golden
(N)
Taylor Foreman
(T)
Allison Bucsan
(A)
Chris Ibegbu
(C)
John Altman
(J)
Susanna Contraras Alcantra
(S)
Alessandro Sette
(A)
Cecilia Lindestam Arlehamn
(C)
Salim Allana
(S)
Angela Campbell
(A)
Sarita Shah
(S)
Susan Ray
(S)
James Brust
(J)
Jeffrey Collins
(J)
Meghan Franczek
(M)
Jenna Daniel
(J)
Anirudh Rao
(A)
Rebecca Goldstein
(R)
Madeleine Kabongo
(M)
Alawode Oladele
(A)
Abraham Aseffa
(A)
Medina Hamza
(M)
Yonas Abebe
(Y)
Fisseha Mulate
(F)
Mekdelawit Wondiyfraw
(M)
Firaol Degaga
(F)
Daniel Getachew
(D)
Dawit Tayachew Bere
(D)
Meaza Zewdu
(M)
Daniel Mussa
(D)
Bezalam Tesfaye
(B)
Selam Jemberu
(S)
Azeb Tarekegn
(A)
Gebeyehu Assefa
(G)
Gutema Jebessa
(G)
Zewdu Solomon
(Z)
Sebsibe Neway
(S)
Jemal Hussein
(J)
Tsegaye Hailu
(T)
Alemayehu Geletu
(A)
Edom Girma
(E)
Million Legesse
(M)
Mitin Wendaferew
(M)
Hirut Solomon
(H)
Zenebech Assefa
(Z)
Mahlet Mekuria
(M)
Misker Kedir
(M)
Eleni Zeleke
(E)
Rediet Zerihun
(R)
Selam Dechasa
(S)
Emebet Haile
(E)
Nahom Getachew
(N)
Firaol Wagari
(F)
Ruth Mekonnen
(R)
Samuel Bayu
(S)
Melat Gebre-Medhin
(M)
Alemayehu Kifle
(A)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Lancet Infect Dis. 2009 Dec;9(12):737-46
pubmed: 19926034
Clin Infect Dis. 2020 Feb 14;70(5):780-788
pubmed: 30958536
Epidemiology. 1999 Jan;10(1):37-48
pubmed: 9888278
Diabetes Res Clin Pract. 2014 Feb;103(2):150-60
pubmed: 24300018
Lancet Diabetes Endocrinol. 2015 May;3(5):323-30
pubmed: 25754415
Sci Rep. 2017 May 17;7(1):1999
pubmed: 28515464
Lancet Diabetes Endocrinol. 2017 Aug;5(8):622-667
pubmed: 28688818
Diabetes Res Clin Pract. 2018 May;139:366-379
pubmed: 29574108
Pan Afr Med J. 2020 Sep 25;37:87
pubmed: 33244350
Clin Infect Dis. 2017 Nov 29;65(12):2060-2068
pubmed: 29059298
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810
Diabetologia. 2012 Aug;55(8):2173-82
pubmed: 22526608
Emerg Infect Dis. 2010 May;16(5):853-5
pubmed: 20409383
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Lancet Diabetes Endocrinol. 2014 Sep;2(9):730-9
pubmed: 25194886
JAMA. 2014 Oct 8;312(14):1460-1
pubmed: 25291583
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):173-9
pubmed: 26884497
MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25
pubmed: 20577159
Clin Infect Dis. 2017 Mar 15;64(6):719-727
pubmed: 27986673
Int J Tuberc Lung Dis. 2019 Jun 1;23(6):669-677
pubmed: 31315698
PLoS Med. 2008 Jul 15;5(7):e152
pubmed: 18630984
Immunology. 2017 Sep;152(1):13-24
pubmed: 28543817
Int J Tuberc Lung Dis. 2018 Jun 1;22(6):686-694
pubmed: 29862955
BMC Public Health. 2020 May 20;20(1):737
pubmed: 32434507
Lancet Diabetes Endocrinol. 2014 Sep;2(9):754-64
pubmed: 25194888
J Infect Dis. 2021 Dec 15;224(12):2064-2072
pubmed: 34008010